Fibrinogen and calcium x phosphate product are predictors of cardiovascular events in the CAPD population

Journal of Nephrology

Volumn 18, Issue 6, 2005, Pages 764-769

  Enia, Giuseppe ^a   Panuccio, Vincenzo ^a   Mallamaci, Francesca ^a   Tripepi, Giovanni ^a   Mandalari, Antonella ^a   Zoccali, Carmine ^a  

^a CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

Calcium x phosphate; Cardiovascular risk; Fibrinogen; Peritoneal dialysis

Indexed keywords

CALCIUM PHOSPHATE; FIBRINOGEN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; FATALITY; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HISTORY; HUMAN; KIDNEY FAILURE; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; UNIVARIATE ANALYSIS;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCIUM; CALCIUM PHOSPHATES; CARDIOVASCULAR DISEASES; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PHOSPHATES; PROGNOSIS; RADIOIMMUNOASSAY; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 30644475622     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol 1998; 11: 239-45.
2. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2002; 13: 1918-27.
3. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58: 353-62.
4. Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol 2004; 15 (suppl 1): S77-80.
5. Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, Han DS. Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis. Perit Dial Int 1998; 18: 387-94.
6. Paniagua R, Frias Y, de Ventura MJ, Rodriguez E, Hurtado ME, Alcantara G, Vazquez R, Ortiz R, Salcedo M, Rios ME, Kaji J, Amato D. C-reactive protein and anti-chlamydia pneumoniae antibodies as risk factors of cardiovascular death in incident patients on peritoneal dialysis. Perit Dial Int 2003; 23: 132-7.
7. Herzig KA, Purdie DM, Chang W, Brown AM, Hawley CM, Campbell SB, Sturtevant JM, Isbel NM, Nicol DL, Johnson DW. Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients? J Am Soc Nephrol 2001; 12: 814-21.
8. Stenvinkel P, Wanner C, Metzger T, Heimburger O, Mallamaci F, Tripepi G, Malatino L, Zoccali C. Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int 2002; 62: 1791-8.
9. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002; 17: 1684-8.
10. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987; 258: 1183-6.
11. Rothwell PM, Howard SC, Power DA, Gutnikov SA, Algra A, van Gijn J, Clark TG, Murphy MF, Warlow CP. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke 2004; 35: 2300-5.
12. Ernst E, Resh KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-63.
13. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. Meta-analysis of prospective studies. JAMA 1998; 279: 1477-82.
14. Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Stancanelli B, Nicocia G, Buemi M. Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. J Intern Med 2003; 254: 132-9.
15. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Nicocia G, Buemi M. Fibrinogen, inflammation and concentric left ventricular hypertrophy in chronic renal failure. Eur J Clin Invest 2003; 33: 561-6.
16. Koch M, Kutkuhn B, Grabensee B, Ritz E. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. Nephrol Dial Transplant 1997; 12: 2603-11.
17. Goldwasser P, Feldman JG, Emiru M, Barth RH. Effect of dialysis modality on plasma fibrinogen concentration: a meta-analysis. Am J Kidney Dis 2004; 44: 941-9.
18. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-17.
19. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO (4), Ca × PO (4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-8.
20. Ketteler M, Gross ML, Ritz E. Calcification and cardiovascular problems in renal failure. Kidney Int Suppl 2005; 67: S120-7.
21. Stompor TP, Pasowicz M, Sulowicz W, Dembinska-Kiec A, Janda K, Wojcik K, Tracz W, Zdzienicka A, Konieczynska M, Klimeczek P, Janusz-Grzybowska E. Trends and dynamics of changes in calcification score over the 1-year observation period in patients on peritoneal dialysis. Am J Kidney Dis 2004; 44: 517-28.
22. Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, Sanderson JE. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003; 14: 159-68.
23. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: 770-9.
24. Harnett, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995; 47: 884-90.
25. Bartens W, Nauck M, Shollmeyer P, Wanner C. Elevated lipoprotein(a) and fibrinogen levels increase the cardiovascular risk in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1996; 16: 27-33.
26. Tomura S, Nakamura Y, Doi M, Ando R, Ida T, Chida Y, Ootsuka S, Shinoda T, Yanagi H, Tsuchiya S, Marumo F. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipids as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1996; 27: 848-54.
27. Giordano M, De Feo P, Lucidi P, de Pascale E, Giordano G, Infantone L, Zoccolo AM, Castellino P. Increased albumin and fibrinogen synthesis in hemodialysis patients with normal nutritional status. J Am Soc Nephrol 2001; 12: 349-54.
28. Goodship TH. Fibrinogen in hemodialysis: the worst of both worlds? Kidney Int 2003; 63: 379-80.
29. Prinsen BH, Rabelink TJ, Beutler JJ, Kaysen GA, De Boer J, Boer WH, Hagen EC, Berger R, De Sain-Van Der Velden MG. Increased albumin and fibrinogen synthesis rate in patients with chronic renal failure. Kidney Int 2003; 64: 1495-504.
30. Russel R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.